Event Details
June 01, 2004
Description
Previous FDA guidance on botanical drugs issued.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024722.jpg
This document is page 86 of a December 2017 Cannabis Investment Report by Ackrell Capital. It discusses the regulatory landscape involving the DEA and FDA, specifically highlighting GW Pharmaceuticals' NDA for Epidiolex and providing six predictions regarding the path to federal cannabis legalization in the US. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
FDA convened meeting to analyze drug data.
Date unknown
Expected FDA approval of a cannabis-derived pharmaceutical
2018-01-01 • USA
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event